To gain insight into the potential functional consequences of altered expression of IL-33 and genes which correlated with IL-33 expression, we performed additional analyses using whole genome RNA-sequencing data from MS-CIS (N = 6) and established MS patients (N = 6) (on no treatment at the time of diagnosis) cohorts. This evidence concerns the gene IL33 and myeloid sarcoma.